OLATUTON 10 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

OCTREOTIDE AS ACETATE

Disponible depuis:

ABIC MARKETING LTD, ISRAEL

Code ATC:

H01CB02

forme pharmaceutique:

POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION

Composition:

OCTREOTIDE AS ACETATE 10 MG

Mode d'administration:

INTRAGLUTEALLY

Type d'ordonnance:

Required

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Domaine thérapeutique:

OCTREOTIDE

indications thérapeutiques:

• Treatment of acromegaly in patients already adequately controlled on standard doses of Octreotide S.C. Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. • Endocrine gastro-entero- pancreatic (GEP) tumors, carcinoid tumors.

Date de l'autorisation:

2022-03-29

Notice patient

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS )PREPARATIONS( – 1986
The medicine is dispensed with a doctor's prescription only
OLATUTON 10 MG
POWDER AND SOLVENT FOR PREPARATION OF PROLONGED-
RELEASE SUSPENSION FOR INJECTION
Composition:
Each vial with powder contains:
Octreotide )as octreotide acetate( 10 mg
OLATUTON 20 MG
POWDER AND SOLVENT FOR PREPARATION OF PROLONGED-
RELEASE SUSPENSION FOR INJECTION
Composition:
Each vial with powder contains:
Octreotide )as octreotide acetate( 20 mg
OLATUTON 30 MG
POWDER AND SOLVENT FOR PREPARATION OF PROLONGED-
RELEASE SUSPENSION FOR INJECTION
Composition:
Each vial with powder contains:
Octreotide )as octreotide acetate( 30 mg
For information regarding inactive ingredients and allergens in
the preparation see section 2 – “Important information about
some of the ingredients of the medicine” and section 6 –
“Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE.
This leaflet contains concise information about the medicine.
If you have additional questions, refer to the doctor or the
pharmacist.
This medicine has been prescribed for you. Do not pass it on
to others. It may harm them even if it seems to you that their
medical condition is similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
Olatuton is intended for:
Treatment of people with acromegaly:
-
Whose illness is sufficiently controlled through treatment
with standard doses of subcutaneous octreotide.
-
When
surgery
or
radiotherapy
are
unsuitable
or
ineffective.
-
To cover the interim period until radiotherapy becomes
fully effective.
Treatment
of
gastro-entero-pancreatic
)GEP(
endocrine
tumors, carcinoid tumors.
THERAPEUTIC CLASS:
Somatostatin analogues.
Olatuton is a synthetic compound derived from somatostatin.
Somatostatin is normally found in the human body, where
it inhibits the release of certain hormones such as growth
hormone. Olatuton has advantages over somatostatin, it is
stronger and its effects last longer.
Acromegaly is a condition in which the